Author: Janine Anthes
Highlights from ASCO 2021: Leukemia – eBook
Jul 23, 2021
ASCO Leukemia Annual Meetingv3 Featuring… ELEVATE-RR: Acalabrutinib demonstrates similar...
Read MorePW Podcast: Will there be a COVID-19 “Olympic Variant”?
Jul 21, 2021
In an interview with Physician’s Weekly, Annie Sparrow, MD, Special Advisor to the...
Read MoreEarly-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab with Stereotactic Body Radiotherapy
Jul 16, 2021
A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among...
Read MorePhysQuiz: A Focus on Tardive dyskinesia
Jul 15, 2021
Are you caught up on what’s happening on advancements in managing tardive dyskinesia? Test...
Read MoreT-DXd Combinations in HER2-positive Metastatic Breast Cancer
Jul 14, 2021
The DESTINY-Breast07 trial will test trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer, as a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion...
Read MoreELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety compared with ibrutinib
Jul 14, 2021
The phase 3 ELEVATE-RR trial was a head-to-head comparison of acalabrutinib versus ibrutinib in previously treated patients with chronic lymphocytic leukemia. The first results of this study demonstrated that acalabrutinib had...
Read MoreELEVATE-TN: long-term efficacy in chronic lymphocytic leukemia
Jul 14, 2021
Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in patients with chronic lymphocytic leukaemia (CLL). Results from the 4-year follow-up of the ELEVATE-TN study...
Read MoreDurvalumab after chemoradiation proven safe in elderly NSCLC patients
Jul 14, 2021
The addition of durvalumab after chemoradiation (CRT) in unresectable stage 3 non-small cell lung cancer (NSCLC) can be safely delivered in elderly patients ≥70 years with comparable improvement in overall survival (OS), as...
Read MoreDoubling overall survival in US veterans with stage 3 non-small cell lung cancer
Jul 14, 2021
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
Read MorePreventing interstitial lung disease in patients on trastuzumab detruxtecan
Jul 14, 2021
Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has durable...
Read MoreThe Importance & Power of Physicians Advocating for Themselves
Jul 13, 2021
In the past, we as physicians have not done a great job of advocacy, and we have largely been removed from policy discussions. The emergence of physician advocacy is a relatively new phenomenon. Why? … Read Full Article...
Read MoreT-DXd Response on Brain Mets HER2+ Breast Cancer
Jul 8, 2021
Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has just as durable...
Read More5-year PACIFIC data hold strong in NSCLC
Jul 8, 2021
Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...
Read More